Corpus Intelligence IC Memo — ADVENTIST HEALTH VALLEJO 2026-04-27 01:02 UTC
IC Memo — ADVENTIST HEALTH VALLEJO
Investment Committee Memorandum | CA | 61 beds | Grade C | EBITDA uplift $2.0M
🛡️ Public data only — no PHI permitted on this instance.
INVESTMENT COMMITTEE MEMORANDUM  ·  CCN 054074

ADVENTIST HEALTH VALLEJO

LOCATIONSOLANO, CA·BEDS61·AS OFApril 27, 2026
C
INVESTABILITY
EBITDA BridgeData Room

1. Target Overview & Investment Thesis

ADVENTIST HEALTH VALLEJO is a 61-bed safety-net/medicaid heavy in SOLANO, CA with $27.1M in net patient revenue and a -18.6% operating margin. The hospital serves a payer mix of 23.7% Medicare, 25.1% Medicaid, and 51.2% commercial.

Thesis: Turnaround. Our ML models identify $2.0M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -18.6% to -11.3% (+736bps).

Net Revenue HCRIS$27.1M
Current EBITDA COMPUTED$-5.1M
Operating Margin COMPUTED-18.6%
Occupancy HCRIS84.8%
Revenue / Bed COMPUTED$445K
Net-to-Gross HCRIS27.9%
Distress Probability ML45.9%

2. Market Context & Competitive Position

414
CA Hospitals
-4.9%
State Median Margin
125
Comparable Hospitals

CA has 414 Medicare-certified hospitals with a median operating margin of -4.9%. The target's margin of -18.6% places it below the state median. Among 125 size-comparable peers (30-122 beds), the median margin is -6.1%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (30-122), prioritizing same-state peers. 125 hospitals in the comp set.

HospitalStateBedsRevenueMargin
ADVENTIST HEALTH VALLEJO (Target)CA61$27.1M-18.6%
RANCHO LOS AMIGOS NATL.REHAB.CCA83$512.6M41.9%
USC NORRIS CANCER HOSPITALCA60$468.7M19.1%
KFH - FREMONTCA100$296.2M-6.6%
QUEEN OF THE VALLEY MEDICAL CECA119$293.8M-16.7%
MERCY HOSPITAL OF FOLSOMCA106$287.8M17.0%
MARSHALL HOSPITALCA111$286.0M-5.9%
KFH - SOUTH SAN FRANCISCOCA120$284.6M-0.0%
LLUMC MURRIETACA111$276.7M-20.3%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $2.0M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$570K+210bp18mo
Cost to Collect4.5%2.5%$543K+200bp12mo
Denial Rate Reduction12.0%6.5%$537K+198bp12mo
A/R Days Reduction5200.0%3800.0%$330K+122bp9mo
Clean Claim Rate88.0%96.0%$17K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$570K
Cost to Collect
$543K
Denial Rate Reduction
$537K
A/R Days Reduction
$330K
Clean Claim Rate
$17K
Total EBITDA Uplift$2.0M
Current EBITDA$-5.1M
+ RCM Uplift+$2.0M
Pro Forma EBITDA$-3.1M
Current Margin-18.6%
Pro Forma Margin-11.3%
WC Released (1x)$1.0M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-7.8M$-13.4M0.00x-100.0%
Base (11x exit)10.0x11.0x$-7.8M$-17.3M0.00x-100.0%
Bull Case9.0x11.0x$-7.0M$-13.2M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-7.0M$-16.5M0.00x-100.0%
Bear Case11.0x10.0x$-8.6M$-20.8M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-8.6M$-25.7M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
MediumElevated Medicaid exposure (25.1%)Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 125 hospitals with 30-122 beds
  • Same-state prioritization (n=126)
  • Comp margins: P25=-23.7% / P50=-6.1% / P75=1.8%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 27, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.